Stasi R, Zinzani P L, Galieni P, Lauta V M, Damasio E, Dispensa E, Dammacco F, Papa G, Tura S
Department of Haematology, University of Rome Tor Vergata, Italy.
Br J Haematol. 1994 Dec;88(4):770-7. doi: 10.1111/j.1365-2141.1994.tb05116.x.
We investigated the prognostic significance of interleukin-10 (IL-10) and soluble interleukin-2 receptor (sIL-2r) levels in the pretreatment serum of 105 individuals with newly-diagnosed aggressive non-Hodgkin's lymphoma (NHL). Commercially available enzyme-linked immunoassay kits were used for cytokine and receptor measurements. Detectable levels of IL-10 were found in 42 (40%) patients at diagnosis, with no correlation with clinico-haematological parameters, but in no control samples (P < 0.001). Pretreatment concentrations of sIL-2r were markedly increased in individuals with NHL when compared to controls (2614 +/- 893 U/ml v 219 +/- 65 U/ml, P < 0.001), patients with stage III/IV presenting higher values than those with stage II disease (3885 +/- 1196 U/ml v 1732 +/- 646 U/ml, P < 0.001). No single parameter was associated with the achievement of complete remission, but the combination of elevated IL-10 and of sIL-2r greater than 3000 U/ml selected a subset of patients with a high probability of failing induction therapy (P < 0.001). Life-table analysis also indicated that patients with these characteristics have a significantly shorter event-free survival. In a multivariate analysis the combination of IL-10 with sIL-2r was found to have greater predictive strength than the combination of IL-10 with beta 2-microglobulin. We conclude that IL-10 and sIL-2r measurements can be expected to improve existing methods of risk assignment in aggressive NHL.
我们研究了105例新诊断的侵袭性非霍奇金淋巴瘤（NHL）患者治疗前血清中白细胞介素-10（IL-10）和可溶性白细胞介素-2受体（sIL-2r）水平的预后意义。使用市售酶联免疫分析试剂盒检测细胞因子和受体水平。诊断时42例（40%）患者可检测到IL-10水平，与临床血液学参数无关，但对照样本中均未检测到（P<0.001）。与对照组相比，NHL患者治疗前sIL-2r浓度显著升高（2614±893 U/ml对219±65 U/ml，P<0.001），Ⅲ/Ⅳ期患者的值高于Ⅱ期疾病患者（3885±1196 U/ml对1732±646 U/ml，P<0.001）。没有单一参数与完全缓解的实现相关，但IL-10升高和sIL-2r大于3000 U/ml的组合选择出了一组诱导治疗失败可能性高的患者（P<0.001）。生存分析还表明，具有这些特征的患者无事件生存期明显缩短。多变量分析发现，IL-10与sIL-2r的组合比IL-10与β2-微球蛋白的组合具有更强的预测力。我们得出结论，检测IL-10和sIL-2r有望改善侵袭性NHL现有风险评估方法。
